Company intelligence / Profile preview

InnVentis

Israel

Ownership: Private
Development stage: Other

Overview

InnVentis collaborates with Metabolon to apply metabolomics in chronic inflammatory diseases, particularly rheumatoid arthritis, aiming to identify drug responder subgroups and enable personalized treatment strategies. The company focuses on real-time disease management and drug dosing optimization.

Therapeutic areas: NeurologyImmunologyPulmonologyDermatology
Industry: Metabolite Diagnostics

Partnerships

Metabolon, Inc.

Beyond the preview

Go deeper on InnVentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnVentis.

Explore the full profile